Literature DB >> 3752419

A longitudinal study of the influence of azathioprine on natural killer cell activity.

B K Pedersen, J M Beyer.   

Abstract

Natural killer (NK) cell activity against K562 target cells was studied in six patients with definite or classical rheumatoid arthritis before and during treatment with azathioprine. Azathioprine induced suppression of NK cell activity, but treatment with azathioprine for 5-8 months was necessary before NK cell activity was completely suppressed. In vitro incubation of mononuclear cells from a healthy donor with azathioprine or 6-mercaptopurine in concentrations not reducing cell viability did not inhibit NK cell activity, nor did sera from patients treated with azathioprine for more than 6 months.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752419     DOI: 10.1111/j.1398-9995.1986.tb02030.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  5 in total

Review 1.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Hodgkin's lymphoma rectosigmoid in a patient with ulcerative colitis on long-term azathioprine therapy.

Authors:  Mehnaaz S Khuroo
Journal:  BMJ Case Rep       Date:  2014-05-20

3.  Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

Authors:  M R J Green; A S M Kennell; M J Larche; M H Seifert; D A Isenberg; M R Salaman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 4.  The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection.

Authors:  Raja Rajalingam
Journal:  Front Immunol       Date:  2016-12-19       Impact factor: 7.561

5.  Circulating NK cells and their subsets in Behçet's disease.

Authors:  M S Hasan; P L Ryan; L A Bergmeier; F Fortune
Journal:  Clin Exp Immunol       Date:  2017-03-13       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.